Blue Bell, Pa. (PRWEB) August 18, 2014
Evolution Consulting & Research, the industry-leading biopharmaceutical consulting and research firm based in Blue Bell, Pa., today announces the official launch of its new name and accompanying website, evolutionconsulting.com. This refreshed branding reflects the firm leadership’s recognition of a shift in client needs from pure marketing research services to strategic consulting partner. Through these strategic partnerships, Evolution provides valuable guidance to pharmaceutical companies looking to better develop and market their products. The firm, founded in 2007, was previously known as Evolution Marketing Research.
“As our team of experts works on the forefront of the biopharma industry, we believe it is our responsibility to respond to the evolving needs of our current and prospective clients, which has increasingly meant serving in a more strategic consulting role,” said Michael Heasley, M.A., M.S., Evolution Partner & Chief Research Officer. “Evolution Consulting & Research better communicates our ongoing commitment to marketing research as the foundation of the industry-leading expertise that our professionals provide as true consulting partners to our clients.”
Along with the new name, Evolution has more formally structured its services into the following areas:
About Evolution Consulting & Research
Evolution Consulting & Research (evolutionconsulting.com), based in Blue Bell, Pa., is an industry-leading biopharmaceutical consulting and research firm whose principals and researchers bring unparalleled experience and health care knowledge to each project. With a focus on marketing research, product development, competitive readiness, and forensic assessment, the firm’s experts possess a deep understanding of the customer and industry landscapes. As a result, each project, team, and methodology is customized to meet the client’s individual needs and goals. Evolution’s wide array of therapeutic area expertise has enabled a history of success in providing strategic direction to its clients, including 15 of the top 20 global pharmaceutical companies.